Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LATIFY: ceralasertib + durvalumab versus docetaxel in previously treated advanced NSCLC
NL-OMON53518Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Ceralasertib plus durvalumab with Docetaxel (2 arms). Primary endpoint: Overall survival. Started Sep 2023; status: recruiting.
02
Drugs
ceralasertibdurvalumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON53518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53518.